Most common types of major bleeds in trials comparing VKAs with DOACs
| Indication . | No. of trials . | Type of major bleed . | VKA . | DOAC . |
|---|---|---|---|---|
| Atrial fibrillation | 4 | All major bleeds | 1769 | 2091 |
| Gastrointestinal | 583 (33%) | 1005 (48%) | ||
| Intracranial | 425 (24%) | 272 (13%) | ||
| VTE treatment | 7 | All major bleeds | 263 | 161 |
| Gastrointestinal | 83 (32%) | 50 (31%) | ||
| Intracranial | 45 (17%) | 17 (11%) |
| Indication . | No. of trials . | Type of major bleed . | VKA . | DOAC . |
|---|---|---|---|---|
| Atrial fibrillation | 4 | All major bleeds | 1769 | 2091 |
| Gastrointestinal | 583 (33%) | 1005 (48%) | ||
| Intracranial | 425 (24%) | 272 (13%) | ||
| VTE treatment | 7 | All major bleeds | 263 | 161 |
| Gastrointestinal | 83 (32%) | 50 (31%) | ||
| Intracranial | 45 (17%) | 17 (11%) |
Only phase 3 trials are included. The number of patients included was higher in the DOAC group than in the VKA group for the studies in atrial fibrillation because the studies with dabigatran and edoxaban included 2 DOAC dose regimens.